REDWOOD CITY, Calif. — Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Atreca is pioneering next-generation approaches to cancer immunotherapy based on the Company’s ability to analyze and target the key phenomenon driving positive outcomes: a patient’s active anti-tumor immune response. Atreca’s Immune Repertoire Capture™ (IRC™) technology delivers the functional antibodies and T cell receptors (TCRs) generated in a patient’s active immune response, in an unbiased fashion with extreme sequence accuracy. With antibodies discovered in the Company’s programs demonstrating activity in vivo, Atreca is advancing a broad pipeline of therapeutic candidates that drive and focus the activity of immune responses unleashed by checkpoint inhibitors and immune activators.
“We are honored to be recognized by FierceBiotech as ‘one of the most potentially transformative private biotech firms’ globally,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and Co-Founder. “Atreca has assembled an exceptional team, together with world-class technical advisors and leadership. We are continuing to work with our valued partners in multiple collaborations across diverse therapeutic areas, while maintaining a broad ownership position in our lead programs in immuno-oncology. We look forward to advancing our programs and continuing to be a standard bearer of the Fierce 15 designation.”
The Fierce 15 celebrates the spirit of being “fierce” — championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fourteenth annual Fierce 15 selection. The 2016 list of “Fierce 15” companies can be found online.
An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 160,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. Atreca is able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T-cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.
EVP and Chief Financial Officer
Rebecca Willumson, 202-824-5050
Justin Jackson, 212-213-0006, ext. 327